SLU-PP-332 Research: ERR Agonists and the Exercise-Mimetic Question

SLU-PP-332 is a synthetic estrogen-related receptor (ERR) agonist studied in mice. What the 2023 ACS Chem Biol paper reported and what is unknown.

Share
SLU-PP-332 Research: ERR Agonists and the Exercise-Mimetic Question

Exercise produces a remarkable range of changes in skeletal muscle, from more mitochondria to shifts in fuel use and fibre type. Researchers have long asked whether some of these changes could be triggered pharmacologically in laboratory models, both to understand the underlying biology and to study conditions where exercise is not possible. Compounds studied in this context are often called "exercise mimetics." SLU-PP-332 is a recent example. This article explains what it is, what the main published study reported and how far the evidence goes.

Overview of this guide

What SLU-PP-332 is

Unlike most products in a research peptide catalogue, SLU-PP-332 is a small synthetic molecule, not a peptide. It was developed by researchers at Saint Louis University, led by Thomas Burris, as an agonist of the estrogen-related receptors (ERRs).

Despite the name, ERRs do not bind estrogen. They are orphan nuclear receptors, meaning no natural ligand was known when they were discovered. There are three: ERRα, ERRβ and ERRγ. ERRα and ERRγ are highly expressed in tissues with high energy demand, such as skeletal muscle and heart, and they regulate genes involved in mitochondrial biogenesis, oxidative metabolism and fatty acid oxidation. They work closely with the coactivator PGC-1α, a well-known regulator of exercise adaptation.

The key study

In 2023, Billon and colleagues published "Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity" in ACS Chemical Biology. They reported that SLU-PP-332 activated all three ERR subtypes in cell-based assays, with the highest potency at ERRα. In mice, administration was associated with increased expression of genes linked to mitochondrial function and oxidative metabolism in skeletal muscle, an increase in type IIa oxidative muscle fibres, and enhanced exercise endurance compared with controls. The authors reported that the acute exercise-like gene-expression response was ERRα-dependent.

Context: earlier exercise-mimetic research

SLU-PP-332 builds on earlier research. A widely cited 2008 Cell paper by Narkar and colleagues, "AMPK and PPARδ agonists are exercise mimetics," reported that pharmacological activation of AMPK with AICAR, and of PPARδ with GW1516, changed oxidative gene expression and endurance measures in mice. That work helped establish the concept. It also illustrates why caution matters, as research on some earlier compounds raised safety concerns in animal studies.

Key points for labs

What remains unknown

  • No human data. The published work is in cell assays and mice.
  • Selectivity. As a pan-ERR agonist, effects may reflect activity at more than one receptor.
  • Long-term effects in models have not been extensively characterized.
  • Independent replication by groups beyond the original developers is still limited.

For these reasons, SLU-PP-332 is best understood as a tool compound for studying ERR biology and exercise signalling, not as a finished answer to the exercise-mimetic question.

Research applications

  • Nuclear receptor pharmacology and ERR signalling.
  • Mitochondrial biogenesis and oxidative metabolism in muscle cells.
  • Comparisons with exercise-induced gene expression in models.
  • Metabolic research in rodent models.

Handling

As a small molecule, SLU-PP-332 is handled differently from peptides. Solubility in plain water may be limited, and labs commonly prepare stock solutions in a suitable organic solvent, such as DMSO, according to their own procedures before diluting for assays. Store solid material cold, dry and protected from light, and record solvent and concentration for every stock.

Sourcing

Morpheus Research supplies SLU-PP-332 10mg for laboratory research. Ask for batch documentation with identity confirmation, and use the contact page for volume orders.

Understanding ERR pharmacology

Because estrogen-related receptors have no known natural ligand, synthetic compounds are especially important tools for studying them. Before SLU-PP-332, ERR research relied heavily on genetic approaches, such as knockout and overexpression models, and on compounds that inhibited ERR activity. Agonists, which increase receptor activity, offered a different way to probe what these receptors do.

ERRs are thought to be constitutively active, meaning they are partly active even without a ligand, through interactions with coactivators such as PGC-1α. An agonist may therefore work by further stabilizing an active conformation or by enhancing coactivator recruitment. Studying these mechanisms is part of what makes such compounds useful in nuclear receptor research.

Distinguishing receptor subtypes

SLU-PP-332 was reported to act on all three ERR subtypes, with the highest potency at ERRα. That makes interpreting results more complex. Approaches researchers use to attribute effects to a specific subtype include:

  • Genetic models lacking one subtype, an approach used to support the ERRα dependence reported in the 2023 study.
  • Knockdown in cell culture using RNA interference.
  • Comparison with more selective compounds, where available.
  • Reporter assays specific to each subtype.

Study design considerations

Researchers designing work with SLU-PP-332 should consider:

  • Vehicle effects. Because organic solvents such as DMSO are often used, vehicle controls at matched solvent concentrations are essential.
  • Exposure and timing. Published work examined both acute gene-expression responses and longer-term changes. These require different designs.
  • Training controls. In animal studies of endurance, comparing a compound group with an exercise-trained group helps show how closely the response resembles exercise.
  • Multiple tissues. ERRs are highly expressed in heart and other tissues as well as skeletal muscle. Effects beyond muscle are relevant to interpretation.

Characterizing a small molecule

Small-molecule documentation differs slightly from peptide certificates. Look for identity by mass spectrometry, and ideally by nuclear magnetic resonance (NMR), plus purity by HPLC. Because SLU-PP-332 is a relatively new research compound, consistent documentation from each lot is particularly worth checking.

Interpreting the 2023 findings

The 2023 paper is a single study from the compound's developers, and its conflict-of-interest statement notes that several authors are stockholders in a company connected to the work. That is common for early tool-compound research and does not invalidate the results, but it makes independent replication especially valuable. Readers should also distinguish between the acute gene-expression response, which the authors reported as ERRα-dependent, and the longer-term changes in muscle fibre type and endurance, which may involve additional mechanisms. Finally, endurance in mice is a model outcome; it shows what the compound did in that system, not what it would do elsewhere.

Frequently asked questions

Is SLU-PP-332 a peptide? No. It is a small synthetic molecule that acts on estrogen-related receptors.

What are estrogen-related receptors? Orphan nuclear receptors (ERRα, β and γ) that regulate energy metabolism genes. They do not bind estrogen.

What did the research report? In mice, the compound was associated with changes in muscle gene expression, oxidative fibres and treadmill performance.

Has it been studied in people? No published human studies are available.

How is it dissolved? Labs commonly use an organic solvent such as DMSO for stock solutions, following their own procedures.

References

  • Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756-771. PMID: 36988910.
  • Narkar VA, Downes M, Yu RT, et al. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415. PMID: 18674809.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.

For research use only. Not for human consumption.